UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):  December 5, 2016

 


 

Blueprint Medicines Corporation

(Exact name of registrant as specified in its charter)

 


 

 

 

 

 

 

Delaware

 

001-37359

 

26-3632015

(State or other jurisdiction

of incorporation)

 

(Commission File Number)

 

(I.R.S. Employer
Identification No.)

 

 

 

 

 

 

38 Sidney Street, Suite 200

Cambridge, Massachusetts

 

02139

(Address of principal executive offices)

 

(Zip Code)

 

 

Registrant’s telephone number, including area code: (617) 374-7580

 

(Former name or former address, if changed since last report)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 7.01         Regulation FD Disclosure .

On December 5, 2016, Blueprint Medicines Corporation hosted an investor conference call and live webcast to discuss initial data from the dose escalation stage of its ongoing Phase 1 clinical trial evaluating BLU-285 for the treatment of advanced systemic mastocytosis.  These data were presented in an oral presentation at the 2016 American Society of Hematology Annual Meeting and Exposition in San Diego, California on December 4, 2016.   BLU-285 is an orally available, potent and highly selective inhibitor that targets D816V mutant KIT. A copy of the slide presentation from the conference call is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01        Financial Statements and Exhibits.

(d) Exhibits.

 

 

 

Exhibit No.

 

Description

99.1

 

Slide presentation by Blueprint Medicines Corporation on December 5, 2016

 

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

BLUEPRINT MEDICINES CORPORATION

 

 

 

 

  Date: December 5, 2016

By:

/s/ Jeffrey W. Albers

 

 

Jeffrey W. Albers

 

 

Chief Executive Officer

 

 

3


 

EXHIBIT INDEX

 

 

 

 

Exhibit No.

 

Description

99.1

 

Slide presentation by Blueprint Medicines Corporation on December 5, 2016

 

4


Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Blueprint Medicines Charts.
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Blueprint Medicines Charts.